vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Lovesac Co (LOVE). Click either name above to swap in a different company.
Lovesac Co is the larger business by last-quarter revenue ($150.2M vs $86.8M, roughly 1.7× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 0.2%). Lovesac Co produced more free cash flow last quarter ($-10.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -22.6%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
The Lovesac Company is an American furniture retailer, specializing in a patented modular furniture system called Sactionals. Sactionals consist of two combinable pieces, “Seats” and “Sides,” as well as custom-fit covers and associated accessories. Lovesac also sells Sacs, a bag seat filled with a proprietary foam mixture.
IOVA vs LOVE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $150.2M |
| Net Profit | — | $-10.6M |
| Gross Margin | 67.4% | 56.1% |
| Operating Margin | -84.7% | -10.5% |
| Net Margin | — | -7.0% |
| Revenue YoY | 17.7% | 0.2% |
| Net Profit YoY | — | -114.0% |
| EPS (diluted) | — | $-0.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $150.2M | ||
| Q3 25 | $67.5M | $160.5M | ||
| Q2 25 | $60.0M | $138.4M | ||
| Q1 25 | $49.3M | $241.5M | ||
| Q4 24 | $73.7M | $149.9M | ||
| Q3 24 | $58.6M | $156.6M | ||
| Q2 24 | $31.1M | $132.6M | ||
| Q1 24 | $715.0K | $250.5M |
| Q4 25 | — | $-10.6M | ||
| Q3 25 | $-91.3M | $-6.7M | ||
| Q2 25 | $-111.7M | $-10.8M | ||
| Q1 25 | $-116.2M | $35.3M | ||
| Q4 24 | — | $-4.9M | ||
| Q3 24 | $-83.5M | $-5.9M | ||
| Q2 24 | $-97.1M | $-13.0M | ||
| Q1 24 | $-113.0M | $31.0M |
| Q4 25 | 67.4% | 56.1% | ||
| Q3 25 | 43.0% | 56.4% | ||
| Q2 25 | 5.5% | 53.7% | ||
| Q1 25 | -0.8% | 60.4% | ||
| Q4 24 | 68.7% | 58.5% | ||
| Q3 24 | 46.2% | 59.0% | ||
| Q2 24 | -0.8% | 54.3% | ||
| Q1 24 | — | 59.7% |
| Q4 25 | -84.7% | -10.5% | ||
| Q3 25 | -140.7% | -5.5% | ||
| Q2 25 | -189.8% | -10.8% | ||
| Q1 25 | -245.8% | 19.7% | ||
| Q4 24 | -117.5% | -5.2% | ||
| Q3 24 | -152.1% | -5.3% | ||
| Q2 24 | -327.6% | -13.5% | ||
| Q1 24 | -16464.6% | 16.1% |
| Q4 25 | — | -7.0% | ||
| Q3 25 | -135.3% | -4.1% | ||
| Q2 25 | -186.2% | -7.8% | ||
| Q1 25 | -235.5% | 14.6% | ||
| Q4 24 | — | -3.3% | ||
| Q3 24 | -142.7% | -3.7% | ||
| Q2 24 | -312.2% | -9.8% | ||
| Q1 24 | -15800.8% | 12.4% |
| Q4 25 | — | $-0.72 | ||
| Q3 25 | — | $-0.45 | ||
| Q2 25 | $-0.33 | $-0.73 | ||
| Q1 25 | $-0.36 | $2.22 | ||
| Q4 24 | $-0.24 | $-0.32 | ||
| Q3 24 | $-0.28 | $-0.38 | ||
| Q2 24 | $-0.34 | $-0.83 | ||
| Q1 24 | $-0.42 | $1.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $23.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $189.3M |
| Total Assets | $913.2M | $495.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $23.7M | ||
| Q3 25 | $300.8M | $34.2M | ||
| Q2 25 | $301.2M | $26.9M | ||
| Q1 25 | $359.7M | $83.7M | ||
| Q4 24 | $323.8M | $61.7M | ||
| Q3 24 | $397.5M | $72.1M | ||
| Q2 24 | $412.5M | $72.4M | ||
| Q1 24 | $356.2M | $87.0M |
| Q4 25 | $698.6M | $189.3M | ||
| Q3 25 | $702.3M | $197.5M | ||
| Q2 25 | $698.5M | $201.2M | ||
| Q1 25 | $767.9M | $216.4M | ||
| Q4 24 | $710.4M | $196.5M | ||
| Q3 24 | $773.5M | $202.1M | ||
| Q2 24 | $768.5M | $205.3M | ||
| Q1 24 | $680.0M | $217.5M |
| Q4 25 | $913.2M | $495.5M | ||
| Q3 25 | $904.9M | $493.7M | ||
| Q2 25 | $907.4M | $483.7M | ||
| Q1 25 | $966.7M | $532.3M | ||
| Q4 24 | $910.4M | $499.7M | ||
| Q3 24 | $991.1M | $481.1M | ||
| Q2 24 | $964.3M | $477.2M | ||
| Q1 24 | $869.8M | $482.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-4.9M |
| Free Cash FlowOCF − Capex | $-61.9M | $-10.2M |
| FCF MarginFCF / Revenue | -71.3% | -6.8% |
| Capex IntensityCapex / Revenue | 10.7% | 3.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-4.9M | ||
| Q3 25 | $-78.7M | $12.2M | ||
| Q2 25 | $-67.4M | $-41.4M | ||
| Q1 25 | $-103.7M | $44.0M | ||
| Q4 24 | $-73.3M | $-4.2M | ||
| Q3 24 | $-59.0M | $6.2M | ||
| Q2 24 | $-98.4M | $-7.0M | ||
| Q1 24 | $-122.3M | $56.3M |
| Q4 25 | $-61.9M | $-10.2M | ||
| Q3 25 | $-89.5M | $7.8M | ||
| Q2 25 | $-74.9M | $-50.0M | ||
| Q1 25 | $-109.9M | $38.7M | ||
| Q4 24 | $-77.5M | $-6.6M | ||
| Q3 24 | $-61.3M | $119.0K | ||
| Q2 24 | $-98.9M | $-14.3M | ||
| Q1 24 | $-126.5M | $49.5M |
| Q4 25 | -71.3% | -6.8% | ||
| Q3 25 | -132.7% | 4.9% | ||
| Q2 25 | -124.9% | -36.1% | ||
| Q1 25 | -222.8% | 16.0% | ||
| Q4 24 | -105.1% | -4.4% | ||
| Q3 24 | -104.6% | 0.1% | ||
| Q2 24 | -317.9% | -10.8% | ||
| Q1 24 | -17685.3% | 19.8% |
| Q4 25 | 10.7% | 3.5% | ||
| Q3 25 | 16.1% | 2.7% | ||
| Q2 25 | 12.4% | 6.2% | ||
| Q1 25 | 12.6% | 2.2% | ||
| Q4 24 | 5.7% | 1.6% | ||
| Q3 24 | 3.9% | 3.9% | ||
| Q2 24 | 1.4% | 5.5% | ||
| Q1 24 | 583.4% | 2.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
LOVE
| Showrooms | $102.7M | 68% |
| Internet | $37.3M | 25% |
| Other | $10.2M | 7% |
